Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGCHealth Care Medicinal Chemicals and Botanical Products USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RGC stock chart
Technical analysisKey statistics
All statistics- EPS (TTM)
- -$0.01
- Dividend yield
- None
- 52-week range
- 4.51 – 69.00
- Day range
- 7.01 – 7.35
- Volume / Avg
- 109.75K / 226.18K
- Beta
- —
- Next earnings
- Oct 28, 2026
52-week range
RGC stock today
Shares of Regencell Bioscience (RGC) finished lower on Oct 7 at $7.11, a drop of 3.27% or $0.24 per share, versus the S&P 500's 0.22% decline. Trading was light, with 109.75K shares changing hands, about 49% of the average daily volume. At this level, RGC sits near the bottom of its 52-week range of $4.51 to $69.00: 89.7% below the high, set on Jan 8, 2026 and 57.6% above the low.
RGC is down 66.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 64.5%. Regencell Bioscience has posted a net loss over the last twelve months (EPS of -$0.01), so its P/E ratio is not meaningful. The company is scheduled to report quarterly results on Oct 28.
Summary generated from market data by MetaCap's automated system. Methodology
About Regencell Bioscience
Company profileRegencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- CEO
- Mr. Yat-Gai Au
- Headquarters
- Causeway Bay
- Employees
- 10
- IPO year
- 2021
- Website
- regencellbioscience.com
Earnings
Earnings history- Next report
- Oct 28, 2026
Regencell Bioscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DFTXDefinium Therapeutics Inc. | 35.09 | -1.49% | $4.71B | vs RGC |
| TRLVTrulieve Cannabis Corp. Subordinate Voting Shares | 10.78 | +1.22% | $2.08B | vs RGC |
| CRONCronos Group Inc. | 3.24 | -1.37% | $1.19B | vs RGC |
| TLRYTilray Brands Inc. | 3.72 | -1.72% | $549.01M | vs RGC |
| GLASGlass House Brands Inc. Subordinate Voting Shares | 5.13 | -0.58% | $483.46M | vs RGC |
| CGCCanopy Growth Corporation | 0.8765 | -1.59% | $393.81M | vs RGC |
| OBIOOrchestra BioMed Holdings Inc. | 5.66 | -3.08% | $340.19M | vs RGC |
| SNDLSNDL Inc. | 1.25 | +1.63% | $307.65M | vs RGC |
Indexes, lists and sector
Regencell Bioscience stock FAQ
What is Regencell Bioscience's stock price today?
RGC last traded at $7.11 as of Oct 7, 4:00 PM EDT, down 3.27% on the day. Prices are delayed at least 15 minutes.
Does Regencell Bioscience pay a dividend?
No. Regencell Bioscience does not currently pay a regular cash dividend.
When is Regencell Bioscience's next earnings date?
Regencell Bioscience is expected to report earnings on Wednesday, October 28, 2026.
Who is Regencell Bioscience's CEO?
Mr. Yat-Gai Au is the chief executive officer of Regencell Bioscience Holdings Limited, which has about 10 employees.
Has RGC ever split its stock?
Yes. The most recent RGC stock split was a 38-for-1 split on Jun 16, 2025.
What is the RGC 52-week high?
The 52-week high for RGC is $69.00 and the 52-week low is $4.51. The stock is currently 89.7% below its high.